Journal Home
Search for

Volume 61, Issue 5, Pages 582-590 (1 March 2007)


View previous. 8 of 27 View next.

Aripiprazole Blocks Reinstatement of Cocaine Seeking in an Animal Model of Relapse

Matthew W. Feltensteina, C. Anthony Altarb, Ronald E. SeeaCorresponding Author Informationemail address

Received 11 January 2006; received in revised form 6 April 2006; accepted 6 April 2006. published online 28 June 2006.

Background

Aripiprazole (Abilify) is an atypical antipsychotic drug primarily characterized by partial agonist activity at dopamine (DA) D2 receptors and low side effects. Based on pharmacologic properties that include a stabilization of mesocorticolimbic DA activity, a pathway implicated in addiction, aripiprazole was tested for its ability to prevent relapse to cocaine seeking in rats.

Methods

We assessed the dose-dependent effects of aripiprazole on conditioned cue-induced and cocaine-primed reinstatement of drug-seeking behavior following chronic intravenous cocaine self-administration in an animal model of relapse.

Results

Aripiprazole potently and dose-dependently attenuated responding on the previously cocaine-paired lever during both reinstatement conditions, with slightly greater efficacy at reducing conditioned-cued reinstatement. Aripiprazole was effective at doses that failed to alter cocaine self-administration, food self-administration, reinstatement of food-seeking behavior, or basal locomotor activity, suggesting selective effects of aripiprazole on motivated drug-seeking behavior.

Conclusions

These results in a relapse model show that aripiprazole can block cocaine seeking without affecting other behaviors. The D2 partial agonist properties of aripiprazole likely account for the blockade of reinstatement of cocaine-seeking behavior. Given its established efficacy and tolerability as a treatment for psychosis, aripiprazole may be an excellent therapeutic choice for reducing craving and preventing relapse in people with cocaine dependency.

a Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina

b Psychiatric Genomics, Inc., Gaithersburg, Maryland.

Corresponding Author InformationAddress reprint requests to Dr. Ronald E. See, Department of Neurosciences, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425

PII: S0006-3223(06)00484-7

doi:10.1016/j.biopsych.2006.04.010


View previous. 8 of 27 View next.